Paulson Richard A.'s Form 4 filing
Karyopharm Therapeutics Inc. (KPTI) · filed Sep 6, 2023
- Accession no.
- 0000950170-23-046721
- Filed
- Sep 6, 2023
- Trade date
- Sep 5, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $4.82K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Paulson Richard A.CIK 0001804460 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 5, 2023 | Common Stock | SSaleDisposed | −3,558 | $1.33 | −$4,732.14 | 798,460 | Direct | |
| Sep 5, 2023 | Common Stock | SSaleDisposed | −64 | $1.32 | −$84.48 | 798,396 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.